Natural killer cell alloreactivity 10 years later

Current Opinion in Hematology

Volumn 19, Issue 6, 2012, Pages 421-426

  Velardi, Andrea ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

allogeneic hematopoietic transplantation; alloreactivity; leukemia; natural killer cells

Indexed keywords

HLA ANTIGEN CLASS 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLELE; ALLOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DIFFERENTIATION; EVENT FREE SURVIVAL; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; T CELL DEPLETION; THERAPY;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; TRANSPLANTATION IMMUNOLOGY;

EID: 84868207797     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283590395     Document Type: Review

References (62)

1. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
2. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110:433-440.
3. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94:333-339.
4. Velardi A, Ruggeri L, Mancusi A, et al. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol 2009; 21:525-530.
5. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-49.
6. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5:201-214.
7. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell 2010; 142:847-856.
8. Joncker NT, Raulet DH. Regulation of NK cell responsiveness to achieve selftolerance and maximal responses to diseased target cells. Immunol Rev 2008; 224:85-97.
9. Elliott JM, Yokoyama WM. Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol 2011; 32:364-372.
10. Haas P, Loiseau P, Tamouza R, et al. NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation. Blood 2011; 117:1021-1029.
11. Schö nberg K, Sribar M, Enczmann J, et al. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 2011; 117: 98-107.
12. Foley B, Cooley S, Verneris MR, et al. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood 2011; 118:2784-2792.
13. Stern M, Ruggeri L, Mancusi A, et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008; 112:2990-2995.
14. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172:644-650.
15. Leung W, Iyengar R, Triplett B, et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005; 174:6540-6545.
16. Pende D, Marcenaro S, Falco M, et al. Antileukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 113:3119-3129.
17. Fernandez NC, Treiner E, Vance RE, et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005; 105:4416-4423.
18. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331-342.
19. Hsu KC, Gooley T, Malkki M, et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transpl 2006; 12:828-836.
20. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLAidentical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105:4878-4884.
21. Hsu KC, Pinto-Agnello C, Gooley T, et al. Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component. Tissue Antigens 2007; 69 (Suppl 1):42-45.
22. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109:5058-5061.
23. Chen DF, Prasad VK, Broadwater G, et al. Differential impact of inhibitory and activating killer Ig-like receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors. Bone Marrow Transplant 2012; 47:817-823.
24. Kasamon YL, Luznik L, Leffell MS, et al. Significance of missing inhibitory KIR ligands in nonmyeloablative, HLA-haploidentical (haplo) BMT with posttransplantation high-dose cyclophosphamide (PT/Cy). ASH Annual Meeting Abstracts 2011; 118:840.
25. Bjö rklund AT, Schaffer M, Fauriat C, et al. NK cells expressing inhibitory KIR for nonself-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 2010; 115:2686-2694.
26. Davies SM, Ruggeri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 2002; 100:3825-3827.
27. Lowe EJ, Turner V, Handgretinger R, et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-nonidentical paediatric bone marrow transplantation. Br J Haematol 2003; 123:323-326.
28. Bornhauser M, Schwerdtfeger R, Martin H, et al. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004; 103:2860-2861.
29. Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch registry. Biol Blood Marrow Transplant 2006; 12:876-884.
30. Krö ger N, Binder T, Zabelina T, et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006; 82:1024-1030.
31. Yabe T, Matsuo K, Hirayasu K, et al., Japan Marrow Donor Program. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 2008; 14: 75-87.
32. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102:814-819.
33. Beelen DW, Ottinger HD, Ferencik S, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005; 105:2594-2600.
34. Elmaagacli AH, Ottinger H, Koldehoff M, et al. Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation 2005; 79:1741-1747.
35. Kröger N, Shaw B, Iacobelli S, et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005; 129:631-643.
36. Dawson MA, Spencer A. Successful use of haploidentical stem-cell transplantation with KIR mismatch as initial therapy for poor-risk myelodysplastic syndrome. J Clin Oncol 2005; 23:4473-4474.
37. Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23:492-500.
38. Brunstein CG, Wagner JE, Weisdorf DJ, et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 2009; 113:5628-5634.
39. Ciceri F, Bonini C, Stanghellini MTL, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a nonrandomised phase I-II study. Lancet Oncol 2009; 10:489-500.
40. Vago L, Forno B, Sormani MP, et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008; 112:3488-3499.
41. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117:3921-3928.
42. Sivori S, Carlomagno S, Falco M, et al. Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 2011; 117:4284-4292.
43. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116:2411-2419.
44. Stringaris K, Adams S, Uribe M, et al. Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLAidentical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant 2010; 16:1257-1264.
45. Albi N, Ruggeri L, Aversa F, et al. Natural killer (NK)-cell function and antileukemic activity of a large population of CD3 +CD8+ T cells expressing NK receptors for major histocompatibility complex class I after 'three-loci' HLA-incompatible bone marrow transplantation. Blood 1996; 87:3993-4000.
46. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-3057.
47. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28:955-959.
48. Curti A, Ruggeri L, D'Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011; 118:3273-3279.
49. Romagné F, André P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009; 114:2667-2677.
50. Jackson SE, Mason GM, Wills MR. Human cytomegalovirus immunity and immune evasion. Virus Res 2011; 157:151-160.
51. Foley B, Cooley S, Verneris MR, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012; 119: 2665-2674.
52. Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol 2011; 11:645-657.
53. Munchel A, Kesserwan C, Symons HJ, et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, posttransplantation cyclophosphamide. Pediatr Rep 2011; 3 (Suppl 2):e15.
54. Dominietto A, Raiola AM, Bruno B, et al. Rapid immune reconstitution following unmanipulated haploidentical BMT with posttransplant high dose cyclophosphamide. ASH Annual Meeting Abstracts 2011; 118:3050.
55. Bashey A, Zhang X, Sizemore CA, et al. T-cell replete haploidentical transplantation using posttransplant cyclophosphamide results in equivalent nonrelapse mortality and disease-free survival compared to transplantation from HLA-identical sibling and matched unrelated donors: a stratified Cox model analysis of two hundred and sixty contemporaneous allogeneic transplants from a single center. ASH Annual Meeting Abstracts 2011; 118:833.
56. Sizemore CA, Bashey A, Sanacore M, et al. Haploidentical transplantation using T-cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. ASH Annual Meeting Abstracts 2011; 118:889.
57. Symons HJ, Chen AR, Luznik L, et al. Myeloablative haploidentical bone marrow transplantation with T cell replete grafts and posttransplant cyclophosphamide: results of a phase II clinical trial. ASH Annual Meeting Abstracts 2011; 118:4151.
58. Raj K, Streetly M, Kazmi M, et al. Peripheral blood progenitor cell (PBPC) transplantation from haploidentical donors following reduced intensity conditioning (RIC) for high-risk hematologic malignancies [abstract]. Biol Blood Marrow Transplant 2012; 18:S331.
59. Wang Y, Liu DH, Xu LP, et al. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant 2011; 17:821-830.
60. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118:282-288.
61. Federmann B, Bornhauser M, Meisner C, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica 2012. [Epub ahead of print]
62. Handgretinger R, Lang P, Feuchtinger TF, et al. Transplantation of TcRab/CD19 depleted stem cells from haploidentical donors: robust engraftment and rapid immune reconstitution in children with high risk leukemia. ASH Annual Meeting Abstracts 2011; 118:1005.